NASOPHARYNGEAL CARCINOMA
Clinical trials for NASOPHARYNGEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NASOPHARYNGEAL CARCINOMA trials appear
Sign up with your email to follow new studies for NASOPHARYNGEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets Hard-to-Treat throat cancer
Disease control Not yet recruitingThis study tests a combination of three drugs (chidamide, toripalimab, and anlotinib) in people with advanced nasopharyngeal cancer that has not responded to at least one prior treatment. The goal is to find the safest dose and see if the drugs can shrink tumors. About 52 adults …
Matched conditions: NASOPHARYNGEAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
New hope for hard-to-treat nose cancer: drug combo plus radiation
Disease control Not yet recruitingThis study tests a new treatment for people whose nose and throat cancer has come back and cannot be removed with surgery. Participants will receive two cycles of a targeted drug (becotatug vedotin) plus an immunotherapy (PD-1 inhibitor), followed by radiation and continued immun…
Matched conditions: NASOPHARYNGEAL CARCINOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
New hope for nose cancer patients: combo therapy targets recurrence
Disease control Not yet recruitingThis study tests a two-step treatment for people whose nasopharyngeal cancer has come back in the same area. First, patients get a targeted drug (MRG003) plus an immunotherapy (PD-1) for six weeks. Then they switch to a chemotherapy pill (capecitabine) plus the same immunotherapy…
Matched conditions: NASOPHARYNGEAL CARCINOMA
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New drug combo aims to improve survival in aggressive nose cancer
Disease control Not yet recruitingThis phase 3 trial tests whether adding an immunotherapy drug (PD-1 antibody) and a targeted therapy (anlotinib) to standard chemoradiation can improve outcomes for people with high-risk nasopharyngeal carcinoma. About 442 adults aged 18-65 with stage III disease will be enrolled…
Matched conditions: NASOPHARYNGEAL CARCINOMA
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
New study aims to unlock clues in nasopharyngeal cancer
Knowledge-focused Not yet recruitingThis study looks at tissue samples from 60 people newly diagnosed with nasopharyngeal cancer that has not spread. Researchers will analyze genetic markers to see if they can predict how well the cancer responds to treatment and how long patients live. The goal is to improve futur…
Matched conditions: NASOPHARYNGEAL CARCINOMA
Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Knowledge-focused
Last updated May 17, 2026 02:05 UTC
-
New study aims to find best next step for tough nasopharyngeal cancer cases
Knowledge-focused Not yet recruitingThis study looks at two different treatment paths for people with advanced nasopharyngeal cancer whose tumors did not shrink enough after two rounds of chemotherapy. One group will get a different type of chemotherapy followed by radiation, while the other group will go straight …
Matched conditions: NASOPHARYNGEAL CARCINOMA
Sponsor: Fujian Cancer Hospital • Aim: Knowledge-focused
Last updated May 14, 2026 12:01 UTC